Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren

References

• Agirbasli M, Papila-Topal N, Ogutmen B, et al. (2007). The blockade of the renin-angiotensin system reverses tacrolimus related cardiovascular toxicity at the histopathological level. JRAAS 8:54–8
   Google Scholar
• Al-Shabanah O, Mansour M, el-Kashef H, al-Bekairi A. (1998). Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int 45:419–27
   PubMedGoogle Scholar
• Atkison P, Joubert G, Barron A, et al. (1995). Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 345:894–6
   PubMed Web of Science ®Google Scholar
• Brandes RP, Kreuzer J. (2005). Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65:16–27
   PubMed Web of Science ®Google Scholar
• Cai H, Griendling KK, Harrison DG. (2003). The vascular NAD(P)H oxidases as therapeutic target in cardiovascular diseases. Trends Pharmacol Sci 24:471–8
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. (2004). A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 77:244–51
   PubMed Web of Science ®Google Scholar
• Clairborne A. (1985). Catalase activity. In Greenwald RA, ed. Handbook of methods for oxygen radical research. Boca Raton (FL): CRC Press, 283–4
   Google Scholar
• Coley KC, Verrico MM, McNamara DM, et al. (2001). Lack of tacrolimus-induced cardiomyopathy. Ann Pharmacother 35:985–9
   PubMed Web of Science ®Google Scholar
• Cox TH, Baillie GM, Baliga P. (1997). Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient. Pharmacotherapy 17:1328–30
   PubMed Web of Science ®Google Scholar
• el-Missiry MA, Othman AI, Amer MA, Abd el-Aziz MA. (2001). Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. Free Radic Res 35:575–81
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L, et al. (2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–81
   PubMed Web of Science ®Google Scholar
• Hodak SP, Moubarak JB, Rodriguez I, et al. (1998). QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 66:535–7
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Ashour OM, Ibrahim YF, et al. (2009). Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 60:373–81
   PubMed Web of Science ®Google Scholar
• Iqbal M, Dubey K, Anwer T, et al. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60:382–90
   PubMed Web of Science ®Google Scholar
• Jarzembowski TM, John E, Panaro F, et al. (2005). Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant 9:117–21
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Kim YS, Hong IC. (1998). Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats. Transplant Proc 30:3596–7
   PubMed Web of Science ®Google Scholar
• Khanna A, Plummer M, Bromberek C, et al. (2002). Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62:2257–63
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Miller LW, Russell SD, et al. (2006). Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6:1377–86
   PubMed Web of Science ®Google Scholar
• Landmesser U, Dikalov S, Price SR, et al. (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J ClinInvest 111:1201–9
   PubMed Web of Science ®Google Scholar
• Lee KC, Chan CC, Yang YY, et al. (2013). Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One 8:e77817
   Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–75
   PubMed Web of Science ®Google Scholar
• Mitamura T, Yamada A, Ishida H, et al. (1994). Tacrolimus (FK506)-induced nephrotoxicity in spontaneous hypertensive rats. J Toxicol Sci 19:219–26
   PubMedGoogle Scholar
• Naesens M, Kuypers DR, Sarwal M. (2009). Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4:481–508
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–8
   PubMed Web of Science ®Google Scholar
• Pappas PA, Weppler D, Pinna AD, et al. (2000). Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 4:45–9
   PubMedGoogle Scholar
• Paradis P, Dali-Youcef N, Paradis FW, et al. (2000). Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 97:931–6
   PubMed Web of Science ®Google Scholar
• Rashikh A, Abul Kalam N, Akhtar M, et al. (2011). Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Hum Exp Toxicol 30:102–9
   PubMed Web of Science ®Google Scholar
• Reynolds ES. (1963). The use of lead citrate at high pH as an electron opaque stain in electron microscopy. J Cell Biol 17:208–12
   PubMed Web of Science ®Google Scholar
• Roberts CA, Stern DL, Radio SJ. (2002). Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. Transplantation 74:817–21
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Gherardi G, et al. (1999). Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–64
   PubMed Web of Science ®Google Scholar
• Sachse A, Wolf G. (2007). Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18:2439–46
   PubMed Web of Science ®Google Scholar
• Sawabe T, Mizuno S, Gondo H, et al. (1997). Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. Transplantation 64:182–3
   PubMed Web of Science ®Google Scholar
• Sedlak J, Lindsay RH. (1968). Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205
   PubMed Web of Science ®Google Scholar
• Singal PK, Segstro RJ, Singh RP, Kutryk MJ. (1985). Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol 1:139–47
   PubMedGoogle Scholar
• Sugino H, Ozono R, Kurisu S, et al. (2001). Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension 37:1394–8
   PubMed Web of Science ®Google Scholar
• Tong J, Ganguly PK, Singal PK. (1991). Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 260:H909–16
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists Collaboration. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527–35
   PubMed Web of Science ®Google Scholar
• Turska-Kmiec A, Jankowska I, Pawłowska J, et al. (2007). Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant 11:319–23
   PubMed Web of Science ®Google Scholar
• Ushio-Fukai M, Alexander RW. (2004). Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264:85–97
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Nistala R, Habibi J, et al. (2010). Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 298:F655–61
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J, et al. (2003). Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308:698–705
   PubMed Web of Science ®Google Scholar
• Yagmurca M, Fadillioglu E, Erdogan H, et al. (2003). Erdosteine prevents doxorubicin-induced cardiotoxicity in rats. Pharmacol Res 48:377–82
   PubMed Web of Science ®Google Scholar
• Zhou X, Yang G, Davis CA, et al. (2004). Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney Int 6:139–47
   Google Scholar